The $30m capital raise for Gelesis, announced yesterday, follows the successful NASDAQ IPO of resTORbio in January. We look forward to the planned filing for approval of Gelesis’ lead weight loss programme Gelesis100 in the US and Europe during 2018. We note that cash (at the company level) and PureTech’s holding in resTORbio in aggregate represent over half of PureTech’s current market capitalisation. We note the positive recent share price performance (+16% YTD, +54% YoY) and reiterate our Buy ....
02 Mar 2018
Successful $30m Gelesis capital raise and broad commercial progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Successful $30m Gelesis capital raise and broad commercial progress
PureTech Health PLC (PRTC:LON) | 224 -5.6 (-1.1%) | Mkt Cap: 605.9m
- Published:
02 Mar 2018 -
Author:
Sheena Berry -
Pages:
3
The $30m capital raise for Gelesis, announced yesterday, follows the successful NASDAQ IPO of resTORbio in January. We look forward to the planned filing for approval of Gelesis’ lead weight loss programme Gelesis100 in the US and Europe during 2018. We note that cash (at the company level) and PureTech’s holding in resTORbio in aggregate represent over half of PureTech’s current market capitalisation. We note the positive recent share price performance (+16% YTD, +54% YoY) and reiterate our Buy ....